November 13, 2017 / 12:09 PM / a month ago

BRIEF-Leap Therapeutics qtrly loss per share $0.73

Nov 13 (Reuters) - Leap Therapeutics Inc-

* Leap Therapeutics reports third quarter 2017 financial results and announces first patient dosed with DKN-01 and Keytruda® (pembrolizumab) in esophagogastric cancer trial

* Leap Therapeutics Inc - ‍cash, cash equivalents and marketable securities totaled $14.2 million at September 30, 2017​

* Leap Therapeutics Inc - ‍net loss was $6.8 million for Q3 of 2017, compared to $7.3 million for same period in 2016​

* Leap therapeutics inc - qtrly loss per share $0.73 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below